Definium Therapeutics Inc (DFTX)
Definium Therapeutics Inc. is a clinical biopharmaceutical company focused on developing product candidates for brain health disorders. Its lead program, DT120, is in Phase 3 development for generalized anxiety disorder, major depressive disorder, and other brain health conditions. The company’s second key candidate, DT402, is a R-enantiomer of 3,4-methylenedioxymethamphetamine and is being studied in Phase 2a trials for autism spectrum disorder. The company was previously known as Mind Medicine (MindMed) Inc. and adopted its current name in January 2026. Definium Therapeutics is headquartered in New York, New York, and its common stock is listed on NASDAQ under the symbol DFTX.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-DFTX
|
$36.49
|
-16.9% Downside
|
Fair
|
$57.80
|
31.6% Upside
|
Undervalued
|
Fair
|
—
|
—
|
—
|
0.0%
|
July 31, 2026
|
-24.5x
|
20.9x
|
—
|
5.681 B
|
5.497 B
|
0.7%
|
98.2%
|
24.7
|
—
|
60.9%
|
